ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
11.24
-0.54 (-4.58%)
At close: Feb 21, 2025, 4:00 PM
11.21
-0.03 (-0.27%)
After-hours: Feb 21, 2025, 5:53 PM EST
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $2.07M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $2.57M, up 8,460.00% year-over-year. In the year 2023, ARS Pharmaceuticals had annual revenue of $30.00K, down -97.72%.
Revenue (ttm)
$2.57M
Revenue Growth
+8,460.00%
P/S Ratio
425.38
Revenue / Employee
$98,769
Employees
26
Market Cap
1.09B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
Dec 31, 2020 | 17.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSPRY News
- 1 day ago - ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients - GlobeNewsWire
- 4 days ago - ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 16 days ago - ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions - Seeking Alpha
- 6 weeks ago - ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript - Seeking Alpha